Last update Dec. 4, 2022


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

A synthetic decapeptide, similar to gonadorelin, analogue of natural luteinizing hormone releasing hormone (LHRH). Indicated in in vitro fertilization treatments before stimulation with exogenous gonadotropins for ovarian stimulation. Subcutaneous administration, a monthly implant. It is also used in carcinomas of the prostate and breast, endometriosis, and uterine fibroids.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and high volume of distribution) make it unlikely that significant amounts will transfer into breastmilk.

Due to its protein nature, it is inactivated in the gastrointestinal tract (Van Leusden 1994, Fraser 1993), not being absorbed (practically zero oral bioavailability), which hinders its transfer into the infant's plasma from breastmilk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.

A similar LHRH analogue, buserelin is excreted in breastmilk in negligible or undetectable amounts and did not cause hormonal alterations in infants breastfed by mothers who were taking it (Dewart 1987), or alterations in lactation. (Fraser 1989)

Increased prolactin has been observed in women treated with gonadorelin analogues and gonadotropins (Cavagna 2005, Kamel 1994, Meldrum 1992), although the findings are not consistent. (Chantilis 1995)

See below the information of these related products:

  • Assisted Reproductive Techniques (ART) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Gonadorelin (GnRH) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)


  • Buserelin (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Goserelin is also known as

Goserelin in other languages or writings:


Goserelin belongs to this group or family:


Main tradenames from several countries containing Goserelin in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.269 daltons
Protein Binding 27 %
VD 0.3 - 0.6 l/Kg
pKa 9.27 -
2.3 hours


  1. PDR.NET Goserelin Drug Summary 2014 Full text (link to original source) Full text (in our servers)
  2. AEPMS Goserelina Ficha técnica 2014 Full text (link to original source) Full text (in our servers)
  3. Cavagna M, Mantese JC, Freitas Gda C, Dzik A, Soares JB, Hameiry Y, Izzo VM, Pinotti JA. Pattern of prolactin secretion after administration of gonadotropin-releasing hormone agonist at the preovulatory phase of intrauterine insemination cycles. Sao Paulo Med J. 2005 Nov 3;123(6):295-7. Epub 2006 Jan 20. Abstract
  4. Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000 Abstract
  5. Perry CM, Brogden RN. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs. 1996 Abstract
  6. Chantilis SJ, Barnett-Hamm C, Byrd WE, Carr BR. The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women. Fertil Steril. 1995 Oct;64(4):698-702. Abstract
  7. Kamel MA, Zabel G, Bernart W, Neulen J, Breckwoldt M. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme. Hum Reprod. 1994 Oct;9(10):1803-6. Abstract
  8. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol. 1994 Sep;8(3):215-22. Review. Abstract
  9. Fraser HM. GnRH analogues for contraception. Br Med Bull. 1993 Jan;49(1):62-72. Review. Abstract
  10. Meldrum DR, Cedars MI, Hamilton F, Huynh D, Wisot A, Marr B. Leuprolide acetate elevates prolactin during ovarian stimulation with gonadotropins. J Assist Reprod Genet. 1992 Jun;9(3):251-3. Abstract
  11. Fraser HM, Dewart PJ, Smith SK, Cowen GM, Sandow J, McNeilly AS. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women. J Clin Endocrinol Metab. 1989 Nov;69(5):996-1002. Abstract
  12. Dewart PJ, McNeilly AS, Smith SK, Sandow J, Hillier SG, Fraser HM. LRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk. Acta Endocrinol (Copenh). 1987 Feb;114(2):185-92. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM